Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Buy" by Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have received a consensus rating of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $36.50.

Several research analysts have issued reports on BCAX shares. HC Wainwright increased their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Wedbush reiterated an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently made changes to their positions in BCAX. Spire Wealth Management acquired a new stake in Bicara Therapeutics in the fourth quarter worth about $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $32,000. Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $33,000. Summit Investment Advisors Inc. acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Virtus ETF Advisers LLC bought a new position in Bicara Therapeutics in the fourth quarter valued at approximately $69,000.

Remove Ads

Bicara Therapeutics Trading Down 7.0 %

Shares of BCAX stock traded down $0.93 during trading hours on Tuesday, hitting $12.42. The company had a trading volume of 746,322 shares, compared to its average volume of 442,511. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The stock's fifty day moving average is $13.28.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.